Last reviewed · How we verify
LevoCept
LevoCept is a selective estrogen receptor modulator (SERM) that modulates estrogen signaling to treat menopausal symptoms and related conditions in women.
LevoCept is a selective estrogen receptor modulator (SERM) that modulates estrogen signaling to treat menopausal symptoms and related conditions in women. Used for Vasomotor symptoms associated with menopause, Menopausal bone health and osteoporosis prevention.
At a glance
| Generic name | LevoCept |
|---|---|
| Also known as | Levonorgestrel-Releasing Intrauterine System |
| Sponsor | Sebela Women's Health Inc. |
| Drug class | Selective Estrogen Receptor Modulator (SERM) |
| Target | Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Women's Health / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
LevoCept acts as a tissue-selective estrogen receptor modulator, binding to estrogen receptors with differential activity across tissues. This allows it to provide estrogen-like benefits in some tissues (such as bone and vasomotor symptom relief) while avoiding unwanted estrogenic effects in others (such as breast and endometrium), making it suitable for menopausal hormone therapy.
Approved indications
- Vasomotor symptoms associated with menopause
- Menopausal bone health and osteoporosis prevention
Common side effects
- Hot flashes
- Headache
- Muscle pain
- Leg cramps
Key clinical trials
- Evaluation of the Efficacy, Safety, and Tolerability of LevoCept (PHASE3)
- Evaluation of the Efficacy and Safety of LevoCept (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LevoCept CI brief — competitive landscape report
- LevoCept updates RSS · CI watch RSS
- Sebela Women's Health Inc. portfolio CI